1/22/2013

Swedish firm Axelar began a Phase I/II trial to assess the efficacy of its investigational drug, AXL1717, in patients with relapsed or progressive malignant astrocytomas. The oral insulin-like growth factor 1 receptor pathway inhibitor is also undergoing a midstage trial for nonsmall-cell lung cancer.

Related Summaries